Janssen is still working hard to promote its big seller Darzalex, and this is now paying off in Canada.
The company has announced that Canadian authorities have approved the injection-based version of this drug, known as Darzalex Faspro, as a treatment for the rare blood disorder AL amyloidosis, which can potentially lead to extensive organ damage. This is the first time that a treatment for this disease has been approved in Canada.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.